EYEN

Hyperion DeFi Inc. (EYEN) | Rumor.io

Hyperion DeFi

EYEN

Attention (50-day avg)0%

Attention rank (50-day avg)#4,949

Bullish sentiment (50-day avg)100%

Price to earnings ratio-0.07

Market capitalization20.6M

Earnings per share-59.8

Dividend yield (TTM)—

Revenue (annual)57.3K

Net income (annual)-49.8M

Social

What share of all stock conversation is about EYEN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Dec 8

Eyenovia, Inc. (EYEN) is a textbook example of a restructuring/credit relief catalyst after disclosing amendments to the Avenue Capital loan in June.
The company's restructuring setup has a near-term catalyst, similar to $MRNO's and $WOLF's experiences, which saw significant share price jumps after bankruptcy court approvals.
EYEN's restructuring plan is expected to cut overall debt by about 70% and reduce cash interest significantly.

Generated by AI

Sentiment

Of the messages about EYEN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	92.05% +12.64
Bearish	—	—	—	7.95% -12.64

Jun 27

$EYEN has solid momentum and is making new highs, with a 29% overnight gain and a strong rebound after negative clinical news.
The company's $50M crypto treasury launch and co-branded validator with Kinetiq & Anchorage Digital are significant catalysts, with the potential to drive further growth.
$EYEN's Optejet Gen-2 is advancing, with FDA filing expected by Q3 2025, and merger talks with Betaliq are underway, which could lead to delivery tech synergy and further price appreciation.

Generated by AI

Topics

Of the messages about EYEN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	81.88%
Controversies	—	—	—	1.29%
Earnings	—	—	—	1.29%
Macro	—	—	—	0%
Technical Analysis	—	—	—	15.53%

Mar 20

Eyenovia (EYEN) has entered into a non-binding letter of intent to effect a reverse merger with Betaliq.
The combined company would leverage two FDA-approved technologies and potentially expand its product portfolio through established partnerships.
The deal values the combined entity at $92M, with EYEN shareholders potentially seeing a stock price surge to ~$7.14.

Generated by AI

Community

Of the messages about EYEN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	39.64%
Newcomers	—	—	100%	60.36%

Regulars· May 25

Eyenovia's stock price jumped 16% on positive results for its MicroLine treatment of presbyopia, a common age-related eye condition.
The company filed a form 8-K with the SEC, reporting on the results of its VISION-1 Phase 3 study, which showed promising data for MicroLine.
Eyenovia's stock price experienced a significant surge, with a 3.6% pop and a current price of $5.25, indicating strong investor interest in the company's micro-line treatment.

Newcomers· Jul 3

New investors are excited about the stock's surge in July 2025, with one user noting a 847% increase and discussing potential earnings and growth factors.
Some newcomers are focused on the company's name change from Eyenovia Inc. to Hyperion DeFi, with one user warning that the SEC dislikes when companies change their names.
Another user is focused on the stock's chart data and is saving it as the company changes its ticker to $HYPD, indicating a shift in focus to the new ticker symbol.

Generated by AI

News

Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi, Inc.

Name change reflects company’s leadership position with its cryptocurrency treasury reserve strategy focused on the HYPE token Company to commence trading...

1mo agoBarchart.com

Eyenovia Announces Closing of $50 Million Private Placement, Successful Accumulation of More Than One Million HYPE Tokens, and Update on its Optejet Development Program

The significant HYPE token position, acquired at an average price of approximately $34 per token, makes Eyenovia the first Nasdaq listed company to run a...

1mo agoBarchart.com

Also Discussed

Investors talking about EYEN also mention

#	Name	Attention
1	BG Staffing IncBGSF	0%new
2	Mega Matrix Inc.MPU	0%0
3	FIAC - Focus Impact Acquisition Corp.	——
4	CERO - CERo Therapeutics Holdings, Inc.	——
5	Lisata Therapeutics, Inc.LSTA	0%0
6	Monarch Casino & Resort, Inc.MCRI	0%0
7	XTI Aerospace, Inc.XTIA	0%+0
8	GlucoTrack Inc.GCTK	0%0
9	Kewaunee Scientific Corporation Common StockKEQU	0%0
10	KACL - Kairous Acquisition Corp. Limited	——

Hyperion DeFi Inc.

Healthcare
Biotechnology

Hyperion DeFi Inc. is a U.S.-based digital asset and DeFi company focused on building a strategic treasury centered on Hyperliquid’s native token, HYPE. The company provides public market access to the Hyperliquid ecosystem through its balance sheet strategy, while also participating in digital asset services and on-chain infrastructure tied to the protocol. Hyperion DeFi’s activities are closely linked to treasury management, token accumulation, and broader engagement with Hyperliquid-based markets, including perpetual futures and spot trading environments. In addition to its digital asset operations, the company maintains a legacy ophthalmic technology segment that includes the Optejet user-filled drug-delivery platform for topical eye care products. Hyperion DeFi Inc. serves as a bridge between decentralized finance exposure and public equity markets, positioning itself as a specialized vehicle for investors seeking access to the Hyperliquid network through a listed company structure.

Website

Location

3090 Nowitzki Way

Dallas, TX, 75219

United States

Social

What share of all stock conversation is about EYEN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Dec 8

Eyenovia, Inc. (EYEN) is a textbook example of a restructuring/credit relief catalyst after disclosing amendments to the Avenue Capital loan in June.
The company's restructuring setup has a near-term catalyst, similar to $MRNO's and $WOLF's experiences, which saw significant share price jumps after bankruptcy court approvals.
EYEN's restructuring plan is expected to cut overall debt by about 70% and reduce cash interest significantly.

Generated by AI

Sentiment

Of the messages about EYEN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	92.05% +12.64
Bearish	—	—	—	7.95% -12.64

Jun 27

$EYEN has solid momentum and is making new highs, with a 29% overnight gain and a strong rebound after negative clinical news.
The company's $50M crypto treasury launch and co-branded validator with Kinetiq & Anchorage Digital are significant catalysts, with the potential to drive further growth.
$EYEN's Optejet Gen-2 is advancing, with FDA filing expected by Q3 2025, and merger talks with Betaliq are underway, which could lead to delivery tech synergy and further price appreciation.

Generated by AI

Topics

Of the messages about EYEN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	81.88%
Controversies	—	—	—	1.29%
Earnings	—	—	—	1.29%
Macro	—	—	—	0%
Technical Analysis	—	—	—	15.53%

Mar 20

Eyenovia (EYEN) has entered into a non-binding letter of intent to effect a reverse merger with Betaliq.
The combined company would leverage two FDA-approved technologies and potentially expand its product portfolio through established partnerships.
The deal values the combined entity at $92M, with EYEN shareholders potentially seeing a stock price surge to ~$7.14.

Generated by AI

Community

Of the messages about EYEN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	39.64%
Newcomers	—	—	100%	60.36%

Regulars· May 25

Eyenovia's stock price jumped 16% on positive results for its MicroLine treatment of presbyopia, a common age-related eye condition.
The company filed a form 8-K with the SEC, reporting on the results of its VISION-1 Phase 3 study, which showed promising data for MicroLine.
Eyenovia's stock price experienced a significant surge, with a 3.6% pop and a current price of $5.25, indicating strong investor interest in the company's micro-line treatment.

Newcomers· Jul 3

New investors are excited about the stock's surge in July 2025, with one user noting a 847% increase and discussing potential earnings and growth factors.
Some newcomers are focused on the company's name change from Eyenovia Inc. to Hyperion DeFi, with one user warning that the SEC dislikes when companies change their names.
Another user is focused on the stock's chart data and is saving it as the company changes its ticker to $HYPD, indicating a shift in focus to the new ticker symbol.

Generated by AI

Hyperion DeFi

Social

Dec 8

Jun 27

Mar 20

Regulars· May 25

Newcomers· Jul 3

Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi, Inc.

Eyenovia Announces Closing of $50 Million Private Placement, Successful Accumulation of More Than One Million HYPE Tokens, and Update on its Optejet Development Program

Also Discussed

Hyperion DeFi Inc.

Company Information

Location

Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi, Inc.

Eyenovia Announces Closing of $50 Million Private Placement, Successful Accumulation of More Than One Million HYPE Tokens, and Update on its Optejet Development Program

Also Discussed

Social

Dec 8

Jun 27

Mar 20

Regulars· May 25

Newcomers· Jul 3